Navigation Links
Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize
Date:10/1/2008

The Samaritan Alzheimer's Rat Model

- Mimics Human Alzheimer's

- Speeds 'Race for Time' to Find Cure

- Saves Valuable Research Money

LAS VEGAS, Oct. 1 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals (OTC Bulletin Board: SPHC) (http://www.samaritanpharma.com) and Taconic Farms, Hudson, New York, are pleased to announce they have inked a worldwide partnering agreement to commercialize "The Samaritan Alzheimer's Rat Model." The "forgetful" rat model is a research tool used by scientists to study the effectiveness of their new drugs to treat Alzheimer's disease. The unique benefits of the rat model lie in its ability,

-- To mimic many features of human Alzheimer's including memory loss,

-- Speed a scientist's "race for time" in finding a cure for the

mind-robbing disease

-- Save scientists valuable research money.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/LAW054)

The rat model is now available exclusively through Taconic. Samaritan will receive royalties on net sales. Financial terms were not disclosed.

"Taconic is extremely pleased to offer researchers a new and potentially invaluable weapon in the war on neurodegenerative disease," said Todd Little, President of Taconic. "The rapid time to disease state of the Samaritan Alzheimer's Rat Model will enable investigators to conduct Alzheimer's drug target screening on a much faster timeline than ever before."

The rat model is published in Pharmacology, 2006;76:19-33

"Taconic provides us with an experienced partner to monetize this unique animal model to 'rat out' Alzheimer's. The rat model is groundbreaking, in that it offers significant advantages over other options previously available for the study of Alzheimer's. We anticipate Taconic achieving and surpassing projected market penetrations in international markets," said Dr. Greeson, CEO, Samaritan Pharmaceuticals.

Samaritan's Phase I, Alzheimer's drug Caprospinol (SP-233), utilized "The Samaritan Alzheimer's Rat Model." and the Morris Water Maze, in an IND enabling, proof of concept study. Treated rats demonstrated Caprospinol's efficacy by,
-- clearing beta-amyloid plaque formation

-- restoring the memory of tested rats

-- protecting mitochondria function

-- protecting cell viability

-- decreasing cell death

Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures."

Samaritan Pharmaceuticals is a biopharmaceutical company committed to bringing innovative life-saving drugs to suffering patients. Samaritan website: http://www.samaritanpharma.com. Please register for upcoming conference calls, news, and events.

Taconic Farms, Inc.

Taconic was founded in 1952 as a family-owned business in New York's Hudson River Valley. Since then, the company has become one of the largest laboratory rodent providers in the world with a reputation for consistently producing high quality, well-defined rats and mice. Taconic has six breeding facilities and three service laboratories in the USA and Europe, a staff of over 900, and a commitment to technological innovation. Taconic website, http://www.taconic.com

Disclaimer

The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 14, 2008. The company undertakes no duty to update forward-looking statements.

Samaritan Pharma Contact: Barrie Fuller 702-735-7001 barriefuller@samaritanpharma.com


'/>"/>
SOURCE Samaritan Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
2. Riverside Partners Sells MicroCal to GE Healthcare
3. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
4. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
5. Satyam Partners with Oracle to Provide Clinical Development Applications
6. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
7. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
8. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
11. NIST and partners identify tiny gold clusters as top-notch catalysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):